Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from ProKidney ( (PROK) ) is now available.
On May 15, 2026, ProKidney reported first-quarter 2026 results and business updates, highlighting progress in its pivotal Phase 3 REGEN-006 (PROACT 1) trial of rilparencel for advanced CKD in patients with diabetes. The company said enrollment for the surrogate eGFR slope endpoint remains on track for completion in mid-2026, with pivotal topline eGFR slope data expected in the second quarter of 2027.
ProKidney noted that PROACT 1 is statistically powered to detect clinically meaningful changes in eGFR slope and benefits from FDA alignment, including recognition of eGFR slope as a surrogate endpoint for an accelerated approval submission. The company also underscored supportive Phase 2 REGEN-007 data, published in January 2026, and ended the quarter with $224.9 million in cash and securities, which it expects will fund operations into mid-2027 despite higher R&D spending and a wider net loss.
The company reported that FDA feedback in a July 2025 meeting confirmed PROACT 1 could support both accelerated and confirmatory approval pathways for rilparencel, reinforcing the strategic importance of the ongoing trial. Together with publication and presentation of Phase 2 data at key nephrology venues, this regulatory alignment enhances ProKidney’s positioning in the competitive CKD therapeutics space as it advances a potential first-in-class cell therapy.
Financially, ProKidney’s first-quarter 2026 results showed increased research and development expenses, primarily from PROACT 1-related clinical and manufacturing costs, alongside reduced general and administrative expenses following prior restructuring efforts. The company closed the quarter with 301,953,977 Class A and B shares outstanding and reaffirmed that its current liquidity should support its operating plan through the anticipated Phase 3 topline readout timeline.
The most recent analyst rating on (PROK) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.
Spark’s Take on PROK Stock
According to Spark, TipRanks’ AI Analyst, PROK is a Neutral.
The score is primarily constrained by weak financial performance—minimal revenue, large losses, and significant cash burn—despite low debt and improved 2025 equity. Technicals are mixed with modest near-term strength but a still-challenged longer-term trend, and valuation support is limited due to negative earnings and no dividend. A positive Phase 3 trial enrollment update helps, but the key milestones are years out.
To see Spark’s full report on PROK stock, click here.
More about ProKidney
ProKidney Corp. is a late clinical-stage biotechnology company specializing in autologous cell therapies for chronic kidney disease, with a lead candidate, rilparencel, aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes. Founded in 2015 and listed on Nasdaq under the ticker PROK, the company focuses on a high-risk population with significant unmet need, targeting Stage 3b/4 CKD patients in the U.S. market.
Average Trading Volume: 816,400
Technical Sentiment Signal: Sell
Current Market Cap: $516.4M
For a thorough assessment of PROK stock, go to TipRanks’ Stock Analysis page.